newsfilter
← Latest News
Business Wire·

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results

- Global strategic collaboration with Astellas to advance PSMA-targeted, PRO-XTEN® dual-masked T-cell engager (TCE) VIR-5500 closed and first patient dosed in Phase 1 dose-expansion cohorts in patients with